Azienda Ospedaliera Per L'Emergenza Cannizzaro — Clinical Trial Site

53 Registered trials

27 Currently recruiting

Organisation

Azienda Ospedaliera Per L'Emergenza Cannizzaro

Location

Catania, Italy

Identifier

ORG-100010331

Address

Via Messina 829, 95126, Italy

Departments

" U.O.C Oncologia Medica"
4110:Ginecologia oncologica
Centro HUB Malattie Infiammatorie Croniche Intestinali (MICI)
Dipartimento di Oncologia Medica
Ginecologia
Gynecology
IT10003: UOC chirurgia generale – IBD Unit
IT10009: UOC chirurgia generale – IBD Unit
Medical Oncology
Medical Oncology Department
N/A
NA
Nefrologia
Oncologia
Oncologia Medica
Oncology
Ostetricia e Ginecologia
S.O.C. di Oncologia Medica
U.O Oncologia Medica
U.O.C di Oncologia Medica
U.O.C. di Oncologia Medica
U.O.C. Oncologia Medica
U.O.D. of Gastroenterology
Unità Operativa Complessa di Ginecologia ed Ostetricia
UO Ostetricia e Ginecologia
UOC Cardiologia
UOC di Oncologia Medica - AOE Cannizzaro (Catania)
UOC Oncologia
UOC Oncologia Medica
UOC UTIC con Cardiologia ed Emodinamica

Clinical trials at this site (53)

Search interface

A PROJECT FOR TWO MULTICENTRE, PROSPECTIVE OPEN LABEL RANDOMIZED CLINICAL STUDIES TO EVALUATE THE EFFECT OF TARGETED THERAPY BASED ON KIDNEY… Pending

2024-517861-18-00 Idiopathic IgA nephropathy (IgAN) 5
A Phase II, Randomized, Trial of Niraparib Versus Best Supportive Careas Maintenance Treatment In Patients With Locally Advanced Or Metastat… Pending

2024-519519-32-00 urothelial cancer 4
Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator’s Choice in Participants With Endometrial Cancer ( R… Pending

2024-519818-31-01 Endometrial Cancer Advanced, Recurrent, Metastatic, or 5
Inavolisib for PIK3CA mutated advanced endometrial cancer: a multicentric, phase II, MITO END-4 trial Recruiting

2025-522981-61-00 endometrial cancer 4 2026-05-19
A Two-Part Phase 3 Study of Sofetabart Mipitecan (LY4170156) in Participants with Platinum-Resistant (Part A) and Platinum-Sensitive (Part B… Recruiting

2025-522255-25-00 Fallopian Tube Neoplasms 5 2026-05-18
A clinical study of sacituzumab tirumotecan for cervical cancer (MK-2870-036) Recruiting

2025-521514-26-00 Persistent, Recurrent, or Newly Diagnosed Metastatic Ce 5 2026-01-26
A clinical study of the anti-cancer effects of an investigational therapy or chemotherapy in patients with recurring uterine cancer Recruiting

2023-507525-42-00 Endometrial cancer 5 2025-12-23
A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab vs Chemotherapy plus Pembrolizumab as First-Line Treatment o… Recruiting

2023-508056-19-00 HER2-Expressing (IHC 3+/IHC 2+), Mismatch Repair Profi 5 2025-10-02
Mirvetuximab soravtansine in combination with bevacizumab for the maintenance treatment of adult patients with FRα-high recurrent platinum-s… Recruiting

2022-501606-35-01 Platinum-sensitive epithelial ovarian, fallopian tube, 11 2024-02-21
A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma Recruiting

2025-524542-10-00 Endometrial cancer 4 2026-04-14
A clinical study of opevesostat and standard hormone therapy in people with prostate cancer (MK-5684-004) Recruiting

2023-504957-11-00 Metastatic castration resistant prostate cancer 5 2026-03-24
Pembrolizumab plus Lenvatinib in vulvar cancer patients: The prospective, multi-cohorts and multicentre, phase 2 MITO VULVA-01 study. Recruiting

2023-509180-24-00 vulvar cancer 4 2026-02-12
A Global Phase III Study of Puxitatug Samrotecan (AZD8205) Monotherapy Compared with Physician’s Choice of Chemotherapy for B7-H4-Selected E… Recruiting

2024-518777-34-00 B7-H4-Selected Advanced/Metastatic Endometrial Cancer. 5 2026-02-11
Study of Trastuzumab Deruxtecan with Bevacizumab Versus Bevacizumab Monotherapy for First-line Maintenance in HER2-Expressing Ovarian Cancer… Recruiting

2024-516982-35-00 Ovarian Cancer 5 2025-09-11
A clinical study of sacituzumab tirumotecan and pembrolizumab in people with endometrial cancer (MK-2870-033) Recruiting

2024-519331-42-00 pMMR endometrial carcinoma 5 2025-08-22
CLINICAL AND HUMORAL IMPACT OF PRIMARY TUMOR ABLATION IN METASTATIC RENAL CELL CARCINOMA TREATED WITH IMMUNOTHERAPY.THE ITALIC-RCC RANDOMIZE… Recruiting

2024-517789-41-00 metastatic or locally advanced renal cell carcinoma 6 2025-07-04
An Open-label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens … Recruiting

2024-517432-21-00 Gynecological Cancers 4 2025-05-30
A Phase 3 Study Comparing BMS-986365 versus Investigator’s Choice of Therapy in Participants with Metastatic Castration-resistant Prostate C… Recruiting

2024-517422-25-00 Metastatic Castration-resistant Prostate Cancer (mCRPC) 5 2025-05-22
COLchicine and Thiamine in Heart Failure due to Ischemic Heart Disease (COLT-HF) Recruiting

2023-506675-96-00 Heart Failure 5 2025-01-23
Olaparib beyond progression compared to platinum chemotherapy after secondary cytoreductive surgery in recurrent ovarian cancer patients. Th… Recruiting

2024-516842-21-00 Recurrent ovarian cancer 5 2025-01-09
MITO 35a: a multicenter, prospective, single arm trial of Olaparib maintenance therapy in newly diagnosed BRCA wild-type advanced ovarian, … Recruiting

2024-516839-27-00 BRCA wild-type advanced ovarian, fallopian tube and pri 4 2024-12-09
An international multicentric randomized phase II evaluating dostarlimab in combination with niraparib versus niraparib alone compared to ch… Recruiting

2024-516782-36-00 metastatic or recurrent endometrial or ovarian carcinos 4 2024-10-15
Phase III study to evaluate the effect of balcinrenone/dapagliflozin in patients with heart failure and impaired kidney function Recruiting

2023-508162-15-00 Chronic HF and comorbid impairment of kidney function w 5 2024-07-12
A Phase 3, Randomized, Open-Label Study of Combination Therapy with Avutometinib plus Defactinib Versus Investigator’s Choice of Treatment i… Recruiting

2023-508204-38-00 Recurrent Low-Grade Serous Ovarian Cancer (LGSOC) 5 2024-07-02